may be the start of both a biotech correction and that will press on some of the most promising of small biotechs in order to free up shares for the institutions and hedge funds to gobble up.
INO has been my best performer this year, so it's been easier for me to stay PATIENT.
I would rather average UP, than down, any day!
With the BS going on in Washington and the factor you mentioned above, this COULD even dip below $2...